Catumaxomab

Catumaxomab (Korjuny, Atnahs Pharma Netherlands B.V.) has 1 EU-approved indication in 1 tumour type. It needs a biomarker result: EpCAM (1).
Approved indications of Catumaxomab
Biomarker requirementRegimenSettingConditions
Solid tumours, tumour-agnostic1
EpCAM-positive
Monotherapy
2L
Malignant ascites; not eligible for further systemic anticancer therapy
Full text of section 4.1 (therapeutic indications)

Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy.

Label history

5 changes to the Korjuny label since 2025, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes